FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Invention represents a method for prediction of a degree of risk of developing metabolic syndrome with underlying antipsychotic therapy in schizophrenic patients. Polymerase chain reaction is used to analyse polymorphisms rs2070744 of gene NOS3 and rs6923761 of gene GLP-1R in real time. According to the invention, among patients with schizophrenia carriers of genotypes of TC or CC polymorphism rs2070744 of gene NOS3 and genotype GG polymorphism rs6923761 gene GLP-1R predict high risk of metabolic syndrome, and carriers of TT genotype polymorphism rs2070744 gene NOS3 and genotypes GA or GG polymorphism rs6923761 of gene GLP-1R are predicted low risk of metabolic syndrome.
EFFECT: invention enables predicting a risk of developing metabolic syndrome accompanying the antipsychotic therapy in schizophrenia patients on the basis of genetic markers.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF EARLY GENETIC DIAGNOSTICS OF RISK FOR DEVELOPING TYPE 2 DIABETES MELLITUS | 2017 |
|
RU2655635C1 |
| METHOD FOR PREDICTING FUNCTIONAL RESULT IN PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2757728C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF EXTRAPYRAMID SIDE EFFECTS DURING THE BACKGROUND OF HALOPERIDOL THERAPY IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS | 2021 |
|
RU2771180C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME DEVELOPMENT IN SCHIZOPHRENIC PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY | 2018 |
|
RU2703424C1 |
| METHOD OF SELECTING TREATMENT TACTICS FOR PATIENTS WITH ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL DISORDERS | 2022 |
|
RU2810798C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF VISCERAL OBESITY IN PATIENTS WITH SCHIZOPHRENIA RECEIVING QUETIAPINE THERAPY | 2017 |
|
RU2659638C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING TYPE 2 DIABETES IN RESIDENTS OF CENTRAL RUSSIA BASED ON GENOTYPING OF THE rs755892 POLYMORPHISM OF THE DNAJB1 GENE | 2023 |
|
RU2803637C1 |
| METHOD FOR GENETIC DIAGNOSTICS OF SUSCEPTIBILITY TO CARDIOVASCULAR DISEASES | 2007 |
|
RU2376372C2 |
| METHOD FOR SUPPORTING MEDICAL DECISIONS ON SELECTION OF ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA IN ORDER TO PREVENT AKATHISIA | 2021 |
|
RU2756614C1 |
| METHOD OF PREDICTING RISK OF DEVELOPING HYPERPROLACTINEMIA IN WOMEN WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC THERAPY | 2023 |
|
RU2810398C1 |
